Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development programThe Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containmentLucid Capital Markets retained ...